CLSTN1

CLSTN1 (calsyntenin-1/alcadein-α) is a neuronal type I transmembrane protein that operates as a kinesin adaptor coupling intracellular cargo transport to axonal and synaptic development (PMID:25009257). In developing sensory neurons it directs transport of Rab5-containing endosomes from the cell body to defined axonal compartments, an activity required for peripheral axon formation and branching (PMID:25009257). At the synapse it co-transports with the adhesion molecule ICAM5 and acts as a negative regulator of ICAM5 surface accumulation, thereby promoting dendritic spine maturation (PMID:31680833). CLSTN1 also forms a tripartite complex with APP and the adaptor X11L/MINT2 that restrains amyloidogenic β-site cleavage of APP in endosomes, so that its loss enhances Aβ generation and amyloid plaque formation (PMID:32467230). Its ectodomain mediates homophilic cell-cell adhesion through amino-terminal cadherin repeats (PMID:25463516). A distinct and well-developed theme is the regulated alternative splicing of CLSTN1 exon 11: isoform switching is causally sufficient to drive epithelial-to-mesenchymal transition and cancer cell invasion across breast, gastric, and pancreatic models, and is controlled by a network of splicing regulators including ESRP1, AKAP8, the DAPK3-TIA1 axis, and STRBP (PMID:31980632, PMID:38114495, PMID:42225952, PMID:38346537). In epithelial and tumor cells the short isoform stabilizes E-cadherin/β-catenin and promotes β-catenin degradation, while CLSTN1 recruitment to cell-cell contacts is repressed by MAP4K signaling, and loss of CLSTN1 increases invasiveness (PMID:38114495, PMID:39762313).

1. 2014 High

   Established CLSTN1's core cellular function as a kinesin adaptor that routes Rab5 endosomes to specific axonal compartments, answering how a transmembrane protein controls axon branching.

   Evidence Morpholino knockdown, genetic mutants, and live in vivo imaging of endosomal trafficking in zebrafish

   PMID:25009257

   Open questions at the time

   • Identity of the kinesin motor and the linkage between cargo selection and branch site is not resolved in the corpus
   • Whether the same transport role operates in mammalian central neurons not addressed here
2. 2014 Medium

   Showed the CLSTN1 ectodomain can mediate homophilic adhesion via cadherin repeats, framing it as a candidate cell-surface adhesion/ligand molecule beyond its intracellular adaptor role.

   Evidence Cloning of zebrafish calsyntenins and bead-sorting adhesion assays

   PMID:25463516

   Open questions at the time

   • No homophilic binding preference detected, leaving the in vivo adhesive partner undefined
   • Single assay (bead-sorting) without cell-based or structural validation
3. 2019 Medium

   Defined a synaptic role for CLSTN1 as a negative regulator of ICAM5 surface delivery, connecting its transport activity to dendritic spine maturation and a Fragile X disease context.

   Evidence shRNA knockdown, surface abundance assays, and rescue in Fmr1 KO neurons and mice

   PMID:31680833

   Open questions at the time

   • Molecular basis of CLSTN1-ICAM5 co-transport not mapped
   • Whether ICAM5 regulation depends on the kinesin-adaptor activity is untested
4. 2020 High

   Demonstrated that CLSTN1 forms an APP/X11L complex that suppresses amyloidogenic APP processing, establishing a protective role against Aβ generation.

   Evidence ALCα-deficient and APP-transgenic mice with co-IP, IHC, and immunoblotting

   PMID:32467230

   Open questions at the time

   • How CLSTN1 loss shifts APP cleavage to the endosomal β-site mechanistically is not detailed
   • Stoichiometry and direct binding interfaces of the tripartite complex not resolved
5. 2020 Medium

   Opened a non-neuronal theme by showing CLSTN1 exon 11 isoform switching, controlled by AKAP8, is causally sufficient to drive EMT and breast cancer metastasis.

   Evidence Genome-wide splicing analysis, isoform manipulation, and EMT/metastasis assays in breast cancer cells

   PMID:31980632

   Open questions at the time

   • Functional difference between the long and short protein isoforms at the molecular level not defined here
   • Single lab and single cancer type
6. 2023 Medium

   Provided a downstream mechanism for the splice isoforms by showing the ESRP1-promoted short isoform stabilizes E-cadherin/β-catenin and drives β-catenin degradation to suppress invasion.

   Evidence Splicing assays, co-IP, ubiquitination assays, and migration/invasion assays in gastric cancer in vitro and in vivo

   PMID:38114495

   Open questions at the time

   • Direct biochemical interaction of the CLSTN1 isoform with the E-cadherin/β-catenin complex not structurally resolved
   • Reconciliation with opposite splicing directionality in other cancers not addressed
7. 2024 Medium

   Extended the splicing-regulator network by showing STRBP/dsHSATII signaling controls CLSTN1 isoform switching sufficient to induce EMT in pancreatic cancer.

   Evidence dsRNA and STRBP manipulation with CLSTN1 isoform and invasion readouts

   PMID:38346537

   Open questions at the time

   • Whether STRBP acts directly on CLSTN1 pre-mRNA or through intermediaries is unresolved
   • Single lab, single cancer model
8. 2024 Medium

   Linked CLSTN1 to epileptogenesis, showing hippocampal knockdown delays and reduces spontaneous seizures in a rat model.

   Evidence Lentiviral RNAi knockdown in rat hippocampus with seizure behavioral monitoring and localization

   PMID:39171546

   Open questions at the time

   • Molecular pathway by which CLSTN1 promotes epileptogenesis not defined
   • Single model and single lab
9. 2025 Medium

   Identified MAP4K signaling as an upstream repressor of CLSTN1 localization to cell-cell contacts, with CLSTN1 loss promoting growth-factor-driven invasiveness in medulloblastoma.

   Evidence MAP4K pharmacological inhibition, knockdown, invasion assays, and immunofluorescence in MB cells

   PMID:39762313

   Open questions at the time

   • Whether MAP4K acts on CLSTN1 protein, trafficking, or splicing is not distinguished
   • Direct substrate relationship not established
10. 2026 Medium

    Resolved an upstream splicing axis by showing DAPK3 phosphorylates and inactivates the exon-11 suppressor TIA1 to enable EMT, and that splice-switching ASOs can reverse the invasive phenotype.

    Evidence RBP screening, splicing reporters, kinase assays, ASO splice-switching, and in vivo circulating tumor cell assays

    PMID:42225952

    Open questions at the time

    • Direct binding of TIA1 to the CLSTN1 exon 11 region not structurally mapped
    • Therapeutic ASO efficacy beyond migration readouts not established
11. 2022 Medium

    Implicated cardiac CLSTN1 in doxorubicin-induced cardiomyopathy through SERCA2 downregulation and PI3K-Akt/CaMK2 hyperphosphorylation.

    Evidence Cardiac-specific overexpression rat model, proteomics, echocardiography, and shRNA knockdown in H9c2 cells

    PMID:36350487

    Open questions at the time

    • Mechanistic link between CLSTN1 and SERCA2/PI3K-Akt signaling not established
    • Physiological relevance of CLSTN1 in normal cardiac tissue not addressed

• It remains unknown how CLSTN1's intracellular kinesin-adaptor/cargo-transport activity mechanistically connects to its protein-isoform-dependent control of cell adhesion and EMT, and whether these are one integrated function or separable activities.
• No structure of CLSTN1 or its complexes in the corpus
• The biochemical difference between exon-11 included vs excluded protein isoforms is not defined
• No unified model linking the neuronal transport role and the epithelial adhesion/EMT role